The Icahn School of Medicine at Mount Sinai has initiated a double-blind, vehicle-controlled clinical trial for PF-07038124, targeting moderate-to-severe seborrheic dermatitis and papulopustular rosacea.

ClinicalAugust 16, 2026

Icahn School of Medicine initiates trial for CaOx stone prevention strategies

The Icahn School of Medicine at Mount Sinai is conducting a randomized controlled trial to compare empiric therapy versus selective therapy for calcium oxalate stone prevention in 80 patients undergoing percutaneous nephrolithotomy.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Therapeutic areas

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.